Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

13.62 -0.29 (-2.12%)
Streaming Delayed Price Updated: 11:41 AM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
From Novocure
Via Business Wire
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
From Novocure
Via Business Wire
NovoCure (NVCR) Q3 2024 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings)
 
Via Benzinga
Why NovoCure Stock Dived by 13% This Week
Investors found the announced changes to the company's C-suite unsettling. 
Via The Motley Fool
Beyond The Numbers: 4 Analysts Discuss NovoCure Stock
 
Via Benzinga
Novocure Appoints Christoph Brackmann as Chief Financial Officer
From Novocure
Via Business Wire
Novocure Reports Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session. 
Via Benzinga
Topics Stocks
Breaking Down NovoCure: 4 Analysts Share Their Views
 
Via Benzinga
A Closer Look at 7 Analyst Recommendations For NovoCure
 
Via Benzinga
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non-small cell lung cancer patients, demonstrating significant... 
Via Benzinga
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
The company could have a long path ahead to reimbursement and, ultimately, sales. 
Via Investor's Business Daily
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Novocure to Report Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
From Novocure
Via Business Wire
Novocure Announces Planned CEO Transition
From Novocure
Via Business Wire
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
From Novocure
Via Business Wire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
From Novocure
Via Business Wire
Chips, Glorious Chips!
Someone's gotta make 'em, and someone's gotta buy 'em. 
Via The Motley Fool
PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
NovoCure (NVCR) Q2 2024 Earnings Call Transcript
NVCR earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q2 2024
NVCR stock results show that NovoCure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Novocure Reports Second Quarter 2024 Financial Results
From Novocure
Via Business Wire
Novocure to Report Second Quarter 2024 Financial Results
From Novocure
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.